VEGFR-TKI– vs mTOR Inhibitor–Targeted Therapies for Non–Clear Cell Renal Cell Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Addressing the Best Treatment for Non-Clear Cell Renal Cell Carcinoma: A Meta-Analysis of Randomised Clinical Trials Comparing VEGFR-TKis Versus mTORi-Targeted Therapies
Eur. J. Cancer 2017 Sep 01;83(xx)237-246, C Ciccarese, R Iacovelli, M Brunelli, F Massari, D Bimbatti, E Fantinel, V De Marco, AB Porcaro, G Martignoni, W Artibani, G TortoraRenal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.